Abstract
BackgroundCurrently there is no way to distinguish or predict therapeutic failure of Tumor Necrosis Factor (TNF) inhibitors in patients with autoimmune diseases, especially rheumatoid arthritis (RA). Elevated Antinuclear Antibodies (ANA)...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
